Clinical features of MYC-R vs MYC-neg, MYC-SH vs MYC-DH, and MYC-IG vs MYC-non-IG partner gene
| . | All patients (n = 574) . | MYC-neg (n = 523) . | MYC-R (n = 51) . | . | MYC-SH (n = 19) . | MYC-DH (n = 32) . | . | MYC-IG (n = 24) . | MYC-non-IG (n = 26) . | . |
|---|---|---|---|---|---|---|---|---|---|---|
| . | n (%) . | n (%) . | n (%) . | P . | n (%) . | n (%) . | P . | n (%) . | n (%) . | P . |
| Median age (range), y | 62 (18-93) | 62 (18-93) | 64 (29-84) | .213 | 65 (29-84) | 62.5 (35-84) | .546 | 69 (29-84) | 60.5 (32-84) | .027 |
| Sex | .285 | .789 | .817 | |||||||
| Male | 308 (53.7) | 277 (53.0) | 31 (60.8) | 12 (63.2) | 19(59.4) | 14 (58.3) | 16 (61.5) | |||
| Female | 266 (46.3) | 246 (47.0) | 20 (39.2) | 7 (36.8) | 13(40.6) | 10 (41.7) | 10 (38.5) | |||
| IPI score | < .001 | .077 | .324 | |||||||
| 0 | 50 (8.7) | 47 (9.0) | 3 (5.9) | 2 (10.5) | 1 (3.1) | 0 (0.0) | 3 (11.5) | |||
| 1 | 119 (20.7) | 115 (22.0) | 4 (7.8) | 1 (5.3) | 3 (9.4) | 1 (4.2) | 3 (11.5) | |||
| 2 | 143 (24.9) | 133 (25.4) | 10 (19.6) | 7 (36.8) | 3 (9.4) | 5 (20.8) | 5 (19.2) | |||
| 3 | 143 (24.9) | 124 (23.7) | 19 (37.3) | 3 (15.8) | 16 (50.0) | 8 (33.3) | 10 (38.5) | |||
| 4 | 91 (15.9) | 85 (16.3) | 6 (11.8) | 2 (10.5) | 4 (12.5) | 4 (16.7) | 2 (7.7) | |||
| 5 | 28 (4.9) | 19 (3.6) | 9 (17.6) | 4 (21.1) | 5 (15.6) | 6 (25.0) | 3 (11.5) | |||
| Age adjusted IPI | .015 | .237 | .338 | |||||||
| 0 | 69 (12.0) | 66 (12.6) | 3 (5.9) | 2 (10.5) | 1 (3.1) | 0 (0.0) | 3 (11.5) | |||
| 1 | 246 (42.9) | 230 (44.0) | 16 (31.4) | 8 (42.1) | 8 (25.0) | 8 (33.3) | 8 (30.8) | |||
| 2 | 205 (35.7) | 183 (35.0) | 22 (43.1) | 5 (26.3) | 17 (53.1) | 10 (41.7) | 11 (42.3) | |||
| 3 | 54 (9.4) | 44 (8.4) | 10 (19.6) | 4 (21.1) | 6 (18.8) | 6 (25.0) | 4 (15.4) | |||
| Ann Arbor stage | .005 | .268 | .187 | |||||||
| I-II | 152 (26.5) | 147 (28.1) | 5 (9.8) | 3 (15.8) | 2 (6.3) | 1 (4.2) | 4 (15.4) | |||
| III-IV | 422 (73.5) | 376 (71.9) | 46 (90.2) | 16 (84.2) | 30 (93.8) | 23 (95.8) | 22 (84.6) | |||
| Performance status (ECOG) | .224 | .860 | .691 | |||||||
| 0-1 | 499 (86.9) | 458 (87.5) | 41 (80.4) | 15 (79.0) | 26 (81.2) | 18 (75.0) | 21 (84.6) | |||
| ≥2 | 75 (13.0) | 65 (12.4) | 10 (19.6) | 4 (21.0) | 6 (18.8) | 6 (25.0) | 4 (15.4) | |||
| LDH > normal | 320 (55.8) | 286 (54.8) | 34 (66.7) | .103 | 10 (52.6) | 24 (75.0) | .101 | 17 (70.8) | 16 (61.5) | .488 |
| Extranodal site >1 | 209 (36.4) | 181 (34.6) | 28 (54.9) | .004 | 10 (52.6) | 18 (56.3) | .802 | 17 (70.8) | 11 (42.3) | .042 |
| Bone marrow involvement | 88 (16.6) | 74 (15.3) | 14 (29.7) | .011 | 5 (29.4) | 9 (30.0) | .966 | 9 (40.9) | 5 (20.8) | .139 |
| Mass >10 cm | 83 (15.3) | 77 (15.6) | 6 (12.8) | .612 | 1 (5.3) | 5 (17.9) | .204 | 5 (20.8) | 1 (4.5) | .101 |
| B symptoms | 183 (31.9) | 169 (32.4) | 14 (27.5) | .472 | 3 (15.8) | 11(34.4) | .150 | 3 (12.5) | 11 (42.3) | .019 |
| β 2 microglobulin (≥3 mg/L) | 160 (33.8) | 141(33.0) | 19 (40.4) | .308 | 6 (33.3) | 13 (44.8) | .435 | 11 (45.8) | 8 (34.8) | .440 |
| Albumin (g/L) ≤35 g/L | 123 (24.6) | 110 (24.2) | 13 (28.3) | .540 | 5 (31.3) | 8 (26.7) | .742 | 9 (39.1) | 4 (18.2) | .121 |
| LNH trials | — | — | — | |||||||
| LNH03-1B | 51 (8.9) | 48 (9.2) | 3 (5.9) | 2 (10.5) | 1 (3.1) | 0 (0.0) | 3 (11.5) | |||
| LNH03-2B | 139 (24.2) | 129 (24.7) | 10 (19.6) | 5 (26.3) | 5 (15.6) | 4 (16.7) | 6 (23.1) | |||
| LNH03-3B | 47 (8.2) | 44 (8.4) | 3 (5.9) | 0(0) | 3 (9.4) | 1 (4.2) | 2 (7.7) | |||
| LNH03-39B | 22 (3.8) | 20 (3.8) | 2 (3.9) | 0(0) | 2 (6.3) | 1 (4.2) | 1 (3.8) | |||
| LNH03-6B | 240 (41.8) | 216 (41.3) | 24 (47.1) | 9 (47.4) | 15 (46.9) | 15 (62.5) | 8 (30.8) | |||
| LNH03-7B | 44 (7.7) | 39 (7.5) | 5 (9.8) | 3 (15.8) | 2 (6.3) | 3 (12.5) | 2 (7.7) | |||
| LNH01-5B | 31 (5.4) | 27 (5.2) | 4 (7.8) | 0 (0) | 4 (12.5) | 0 (0.0) | 4 (15.4) | |||
| Arm of treatment | — | — | — | |||||||
| R-ACVBP | 189 (32.9) | 176 (33.7) | 13 (25.5) | 2 (10.5) | 11 (34.4) | 2 (8.3) | 11 (42.3) | |||
| R-ACVBP+ASCT | 22 (3.8) | 20 (3.8) | 2 (3.9) | 0 (0) | 2 (6.3) | 1 (4.2) | 1 (3.8) | |||
| R-CHOP21 | 200 (34.8) | 179 (34.2) | 21 (41.2) | 9 (47.4) | 12 (37.5) | 10 (41.7) | 11 (42.3) | |||
| R-CHOP14 | 119 (20.7) | 109 (20.8) | 10 (19.6) | 5 (26.3) | 5 (15.6) | 8 (33.3) | 1 (3.8) | |||
| R-mini-CHOP21 | 44 (7.7) | 39 (7.5) | 5 (9.8) | 3 (15.8) | 2 (6.3) | 3 (12.5) | 2 (7.7) | |||
| Arm of treatment | — | — | — | |||||||
| R-ACVBP | 211 (36.8) | 196 (37.5) | 15 (29.4) | 2 (10.5) | 13 (40.6) | 3 (12.5) | 12 (46.2) | |||
| R-CHOP | 363 (63.2) | 327 (62.5) | 36 (70.6) | 17 (89.5) | 19 (59.4) | 21 (87.5) | 14 (53.8) |
| . | All patients (n = 574) . | MYC-neg (n = 523) . | MYC-R (n = 51) . | . | MYC-SH (n = 19) . | MYC-DH (n = 32) . | . | MYC-IG (n = 24) . | MYC-non-IG (n = 26) . | . |
|---|---|---|---|---|---|---|---|---|---|---|
| . | n (%) . | n (%) . | n (%) . | P . | n (%) . | n (%) . | P . | n (%) . | n (%) . | P . |
| Median age (range), y | 62 (18-93) | 62 (18-93) | 64 (29-84) | .213 | 65 (29-84) | 62.5 (35-84) | .546 | 69 (29-84) | 60.5 (32-84) | .027 |
| Sex | .285 | .789 | .817 | |||||||
| Male | 308 (53.7) | 277 (53.0) | 31 (60.8) | 12 (63.2) | 19(59.4) | 14 (58.3) | 16 (61.5) | |||
| Female | 266 (46.3) | 246 (47.0) | 20 (39.2) | 7 (36.8) | 13(40.6) | 10 (41.7) | 10 (38.5) | |||
| IPI score | < .001 | .077 | .324 | |||||||
| 0 | 50 (8.7) | 47 (9.0) | 3 (5.9) | 2 (10.5) | 1 (3.1) | 0 (0.0) | 3 (11.5) | |||
| 1 | 119 (20.7) | 115 (22.0) | 4 (7.8) | 1 (5.3) | 3 (9.4) | 1 (4.2) | 3 (11.5) | |||
| 2 | 143 (24.9) | 133 (25.4) | 10 (19.6) | 7 (36.8) | 3 (9.4) | 5 (20.8) | 5 (19.2) | |||
| 3 | 143 (24.9) | 124 (23.7) | 19 (37.3) | 3 (15.8) | 16 (50.0) | 8 (33.3) | 10 (38.5) | |||
| 4 | 91 (15.9) | 85 (16.3) | 6 (11.8) | 2 (10.5) | 4 (12.5) | 4 (16.7) | 2 (7.7) | |||
| 5 | 28 (4.9) | 19 (3.6) | 9 (17.6) | 4 (21.1) | 5 (15.6) | 6 (25.0) | 3 (11.5) | |||
| Age adjusted IPI | .015 | .237 | .338 | |||||||
| 0 | 69 (12.0) | 66 (12.6) | 3 (5.9) | 2 (10.5) | 1 (3.1) | 0 (0.0) | 3 (11.5) | |||
| 1 | 246 (42.9) | 230 (44.0) | 16 (31.4) | 8 (42.1) | 8 (25.0) | 8 (33.3) | 8 (30.8) | |||
| 2 | 205 (35.7) | 183 (35.0) | 22 (43.1) | 5 (26.3) | 17 (53.1) | 10 (41.7) | 11 (42.3) | |||
| 3 | 54 (9.4) | 44 (8.4) | 10 (19.6) | 4 (21.1) | 6 (18.8) | 6 (25.0) | 4 (15.4) | |||
| Ann Arbor stage | .005 | .268 | .187 | |||||||
| I-II | 152 (26.5) | 147 (28.1) | 5 (9.8) | 3 (15.8) | 2 (6.3) | 1 (4.2) | 4 (15.4) | |||
| III-IV | 422 (73.5) | 376 (71.9) | 46 (90.2) | 16 (84.2) | 30 (93.8) | 23 (95.8) | 22 (84.6) | |||
| Performance status (ECOG) | .224 | .860 | .691 | |||||||
| 0-1 | 499 (86.9) | 458 (87.5) | 41 (80.4) | 15 (79.0) | 26 (81.2) | 18 (75.0) | 21 (84.6) | |||
| ≥2 | 75 (13.0) | 65 (12.4) | 10 (19.6) | 4 (21.0) | 6 (18.8) | 6 (25.0) | 4 (15.4) | |||
| LDH > normal | 320 (55.8) | 286 (54.8) | 34 (66.7) | .103 | 10 (52.6) | 24 (75.0) | .101 | 17 (70.8) | 16 (61.5) | .488 |
| Extranodal site >1 | 209 (36.4) | 181 (34.6) | 28 (54.9) | .004 | 10 (52.6) | 18 (56.3) | .802 | 17 (70.8) | 11 (42.3) | .042 |
| Bone marrow involvement | 88 (16.6) | 74 (15.3) | 14 (29.7) | .011 | 5 (29.4) | 9 (30.0) | .966 | 9 (40.9) | 5 (20.8) | .139 |
| Mass >10 cm | 83 (15.3) | 77 (15.6) | 6 (12.8) | .612 | 1 (5.3) | 5 (17.9) | .204 | 5 (20.8) | 1 (4.5) | .101 |
| B symptoms | 183 (31.9) | 169 (32.4) | 14 (27.5) | .472 | 3 (15.8) | 11(34.4) | .150 | 3 (12.5) | 11 (42.3) | .019 |
| β 2 microglobulin (≥3 mg/L) | 160 (33.8) | 141(33.0) | 19 (40.4) | .308 | 6 (33.3) | 13 (44.8) | .435 | 11 (45.8) | 8 (34.8) | .440 |
| Albumin (g/L) ≤35 g/L | 123 (24.6) | 110 (24.2) | 13 (28.3) | .540 | 5 (31.3) | 8 (26.7) | .742 | 9 (39.1) | 4 (18.2) | .121 |
| LNH trials | — | — | — | |||||||
| LNH03-1B | 51 (8.9) | 48 (9.2) | 3 (5.9) | 2 (10.5) | 1 (3.1) | 0 (0.0) | 3 (11.5) | |||
| LNH03-2B | 139 (24.2) | 129 (24.7) | 10 (19.6) | 5 (26.3) | 5 (15.6) | 4 (16.7) | 6 (23.1) | |||
| LNH03-3B | 47 (8.2) | 44 (8.4) | 3 (5.9) | 0(0) | 3 (9.4) | 1 (4.2) | 2 (7.7) | |||
| LNH03-39B | 22 (3.8) | 20 (3.8) | 2 (3.9) | 0(0) | 2 (6.3) | 1 (4.2) | 1 (3.8) | |||
| LNH03-6B | 240 (41.8) | 216 (41.3) | 24 (47.1) | 9 (47.4) | 15 (46.9) | 15 (62.5) | 8 (30.8) | |||
| LNH03-7B | 44 (7.7) | 39 (7.5) | 5 (9.8) | 3 (15.8) | 2 (6.3) | 3 (12.5) | 2 (7.7) | |||
| LNH01-5B | 31 (5.4) | 27 (5.2) | 4 (7.8) | 0 (0) | 4 (12.5) | 0 (0.0) | 4 (15.4) | |||
| Arm of treatment | — | — | — | |||||||
| R-ACVBP | 189 (32.9) | 176 (33.7) | 13 (25.5) | 2 (10.5) | 11 (34.4) | 2 (8.3) | 11 (42.3) | |||
| R-ACVBP+ASCT | 22 (3.8) | 20 (3.8) | 2 (3.9) | 0 (0) | 2 (6.3) | 1 (4.2) | 1 (3.8) | |||
| R-CHOP21 | 200 (34.8) | 179 (34.2) | 21 (41.2) | 9 (47.4) | 12 (37.5) | 10 (41.7) | 11 (42.3) | |||
| R-CHOP14 | 119 (20.7) | 109 (20.8) | 10 (19.6) | 5 (26.3) | 5 (15.6) | 8 (33.3) | 1 (3.8) | |||
| R-mini-CHOP21 | 44 (7.7) | 39 (7.5) | 5 (9.8) | 3 (15.8) | 2 (6.3) | 3 (12.5) | 2 (7.7) | |||
| Arm of treatment | — | — | — | |||||||
| R-ACVBP | 211 (36.8) | 196 (37.5) | 15 (29.4) | 2 (10.5) | 13 (40.6) | 3 (12.5) | 12 (46.2) | |||
| R-CHOP | 363 (63.2) | 327 (62.5) | 36 (70.6) | 17 (89.5) | 19 (59.4) | 21 (87.5) | 14 (53.8) |
ECOG, Eastern Cooperative Oncology Group; LNH, non-Hodgkin lymphoma; MYC-neg, DLBCL without MYC gene rearrangement.